Sweden Pharmaceuticals & Healthcare Report Q1 2014
Published by Business Monitor International
on Nov 20, 2013
, 116 pages
PDF - Download Now with 3 Quarterly Updates format - Download Now
BMI View: In addition to a decline in the overall value of the Swedish pharmaceutical market in the coming five years, we envisage the same trend in the number of clinical trials conducted in a country known for its research capabilities. As the costs of pharmaceutical studies continues to rise, Sweden will struggle to attract investment in this area, with negative ramifications for the industry as a whole as well as for the wider economy, especially given the downward pressure on pharmaceutical prices. Nevertheless, we expect to see further positive developments in the research and development (R&amp;D) field, as the country offers clear advantages in this arena.